Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300

Annals of Oncology

Volumn 29, Issue 10, 2018, Pages 2052-2060

  Bang, Y J ^a   Yanez Ruiz E ^b   Van Cutsem, E ^c   Lee, K W ^d   Wyrwicz, L ^e   Schenker, M ^f   Alsina, M ^g   Ryu, M H ^h   Chung, H C ⁱ   Evesque, L ^j   Al Batran, S E ^k   Park, S H ^l   Lichinitser, M ^m   Boku, N ⁿ   Moehler, M H ^o   Hong, J ^p   Xiong, H ^p   Hallwachs, R ^q   Conti, I ^p   Taieb, J ^r  

^a Seoul National University College of Medicine   (South Korea)

^b UNIVERSIDAD DE LA FRONTERA   (Chile)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d Seoul National University Bundang Hospital   (South Korea)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f Oncologie Medicala   (Romania)

^g VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^h University of Ulsan College of Medicine   (South Korea)

ⁱ Yonsei University College of Medicine   (South Korea)

^j CENTRE ANTOINE LACASSAGNE   (France)

^k KRANKENHAUS NORDWEST   (Germany)

^l Samsung Medical Center   (South Korea)

^m N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

ⁿ NATIONAL CANCER CENTER HOSPITAL   (Japan)

^o JOHANNES GUTENBERG UNIVERSITY   (Germany)

^p Global Clinical Development Immuno Oncology   (United States)

^q MERCK KGAA   (Germany)

^r Laboratoire d'Excellence GR Ex   (France)

more..

Author keywords

Avelumab; Chemotherapy; Gastric cancer; Gastro oesophageal junction cancer; PD L1; Phase III

Indexed keywords

AVELUMAB; IRINOTECAN; PACLITAXEL; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ARTICLE; AUTOIMMUNE HEPATITIS; COLITIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGUS CANCER; FEMALE; GASTROESOPHAGEAL CANCER; HUMAN; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; STOMACH CANCER; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE TIME; ADENOCARCINOMA; ADOLESCENT; AGED; CLINICAL PRACTICE; CLINICAL TRIAL; COLLOID CARCINOMA; DECISION MAKING; DECISION SUPPORT SYSTEM; ESOPHAGUS TUMOR; FOLLOW UP; GASTROESOPHAGEAL JUNCTION; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; PAPILLARY CARCINOMA; PATHOLOGY; PROGNOSIS; SIGNET RING CARCINOMA; STOMACH TUMOR; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PAPILLARY; CARCINOMA, SIGNET RING CELL; CHOICE BEHAVIOR; DECISION SUPPORT TECHNIQUES; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; IRINOTECAN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PRACTICE PATTERNS, PHYSICIANS'; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 85055128316     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy264     Document Type: Article

References (24)

1. Noone AM, Howlader N, Krapcho M et al. SEER cancer statistics review, 1975, 2015; https://seer.cancer.gov/csr/1975_2015.
2. Kang YK, Boku N, Satoh T et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390(10111): 2461-2471.
3. Wagner AD, Syn NL, Moehler M et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017; 8: CD004064.
4. Digklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. WJG 2016; 22(8): 2403-2414.
5. Smyth EC, Verheij M, Allum W et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27(Suppl 5): v38-v49.
6. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. V2.2018; https://www.nccn.org/professionals/physician_gls/pdf/gastric. pdf (10 May 2018, date last accessed).
7. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697.
8. Salati M, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO Open 2017; 2(3): e000206.
9. Tabernero J, Shitara K, Dvorkin M et al. Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). Ann Oncol 2018; 29(Suppl 5): mdy208.001.
10. Japanese Gastric Cancer Association Japanese gastric cancer treatment guidelines 2014 (ver.4). Gastric Cancer 2017; 20(1): 1-19.
11. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014; 513(7517): 202-209.
12. Amatatsu M, Arigami T, Uenosono Y et al. Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. Cancer Sci 2018; 109(3): 814-820.
13. Kawazoe A, Kuwata T, Kuboki Y et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer 2017; 20(3): 407-415.
14. Yuan J, Zhang J, Zhu Y et al. Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance. Oncotarget 2016; 7(26): 39671-39679.
15. Wang L, Zhang Q, Ni S et al. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. Cancer Med 2018; 7(6): 2612-2620.
16. Fuchs CS, Doi T, Jang RW et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol 2018; 4(5): e180013.
17. Patel MR, Ellerton J, Infante JR et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 2018; 19(1): 51-64.
18. Nghiem P, Bhatia S, Brohl AS et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: a registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol 2018; 36(Suppl): abstr 9507.
19. Chung H, Arkenau HT, Lee J et al. Avelumab (anti-PD-L1) as first-line maintenance (1L mn) or second-line (2L) therapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC): updated phase Ib results from the JAVELIN Solid Tumor trial. Oral presentation at American Association for Cancer Research Annual Meeting 2018, 14-18 April 2018, Chicago, IL, Abstr CT111.
20. Hironaka S, Shitara K, Iwasa S et al. Avelumab (MSB0010718C; anti-PD-L1) in Japanese patients with advanced gastric cancer: results from a phase 1b trial. Ann Oncol 2016; 27(Suppl 7): mdw521.047.
21. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45(2): 228-247.
22. Shitara K, Ozguroglu M, Bang YJ et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018; 392(10142): 123-133.
23. Zheng Y, Zhu XQ, Ren XG. Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2017; 96(24): e6884.
24. Gu L, Chen M, Guo D et al. PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS One 2017; 12(8): e0182692.